Successful Treatment of Erdheim-Chester Disease, a Non-Langerhans Cell Histiocytosis, with Interferon-alpha

By Fadi Braithè ¹, Cynthia Boxrud ³, Bita Esmaeli ² and Razelle Kurzrock ¹.

¹Phase I Program, Division of Cancer Medicine and the University of Texas Graduate School of Biomedical Sciences at Houston, Texas; ²Section of Ophthalmology, Department of Plastic Surgery, MD Anderson Cancer Center, Houston, Texas and ³Jules Stein Eye Institute, UCLA, Santa Monica, California.

Corresponding author:

Razelle Kurzrock, M.D., F.A.C.P.
Professor of Medicine
Director, Phase I Program, Division of Cancer Medicine
M.D. Anderson Cancer Center,
1515 Holcombe Blvd, Unit 422
Houston, TX 77030-4009
Tel: 713-794-1226; Fax: 713-745-2374

Word count: 1195
Abstract (146 words)

Erdheim-Chester disease is a rare non-Langerhans histiocytosis with multisystem involvement. To date, there is no standard treatment for this disorder, and over half of the patients succumb within three years. Because interferon-alpha promotes the terminal differentiation of histiocytes and dendritic cells, we hypothesized that this molecule would be a useful therapy for Erdheim-Chester disease. We therefore treated three patients with advanced disease with interferon-alpha at a starting dose of 3 to 6 $\times 10^6$ units, which was later reduced, during maintenance, to $1 \times 10^6$ units s.c. three times per week. Marked improvement was noted in all patients, with substantial retro-orbital disease regression within one month. Improvement in bone lesions, pain, diabetes insipidus and other manifestations was gradual over many months. Responses were durable (3+ to 4.5+ years). Our observations suggest that this well-tolerated therapy has a significant impact on the course and outcome of Erdheim-Chester disease.
Introduction

In 1930, William Chester described the first two cases of “lipoid granulomatosis”, later renamed Erdheim-Chester disease [1]. This illness represents a rare non-Langerhans histiocytosis with particular tropism for connective and adipose tissues. Clinical features range from a focal asymptomatic process to a multisystem, rapidly fatal, infiltrative disease with a total of about 250 cases described in the literature [2-7]. Typically it affects adults of both genders, with symmetric osteosclerosis of the long bones sparing the epiphyses [2,3]. The histiocytes mainly infiltrate bones, pituitary, orbit, retroperitoneum and central nervous system [2-5]. The pathology is characterized by large, foamy or eosinophilic cytoplasm lipid-laden CD68-positive, CD1a and S100 negative histiocytes lacking any Birbeck granules; and the pathognomonic Touton-like giant cells, which are multinucleated cells with the nuclei organized in a wreath-like ring and a xanthomatous cytoplasm [4,6,8].

There is no standard treatment for Erdheim-Chester disease. Unfortunately, about 60% of patients succumb to their disease within 32 months of presentation [2]. Of interest, researchers reported that interferon-α results in terminal differentiation of histiocytes and dendritic cells [9,10]. We therefore administered interferon-α to three patients with Erdheim-Chester disease. This treatment resulted in durable responses, with the longest ongoing at four years.
Study design

Patient 1:

A 55-year-old man with a four-year history of diabetes insipidus, presented with rapidly decreasing vision, orbital pain and striking exophthalmos. Previous medical history included hairy cell leukemia, which had been in complete remission for several years after treatment with 2-chlorodeoxyadenosine. The ophthalmologic examination revealed restricted extra-ocular movements, bilateral visual acuity of 20/30 and a Hertel exophthalmometry measurement of 23 mm (normal: 12-20 mm). Fundal exam suggested compressive optic neuropathy. Magnetic resonance imaging (MRI) of the orbit showed massive retrobulbar infiltration (Figure 1A). Bone marrow aspiration and thyroid panels were normal. The patient’s vision and orbital pain continued to worsen (20/80 in the right eye and 20/200 in the left eye), with severe bilateral visual field deficit despite high dose of corticosteroids. The diabetes insipidus, ocular symptoms and the technetium-99m labeled methylene diphosphonate (99mTc-MDP) bone scan findings of diffuse osteosclerosis of the long bones was compatible with the diagnosis of Erdheim-Chester disease. Furthermore, abdominal computed tomography scan revealed perinephric soft tissue infiltrate and biopsy was consistent with Erdheim Chester disease (Figure 1C).

The patient was treated with 3x10^6 units of s.c. interferon-α three times per week. Within one month he was able to taper off corticosteroids, and showed recovery of his visual acuity and visual fields. Repeat MRI of the orbits three months later showed substantial improvement [11]. The patient’s persistent fatigue resolved with a reduction of the interferon-α dose down to one million units three times per week. Four years later, the patient remains asymptomatic on this maintenance dose. His MRI shows further decrease in his retro-orbital mass size and its inflammatory activity.
(Figure 1B). His diabetes insipidus has also improved with a 87.5% reduction of his
daily desmopressin dose.

Patient 2:

A 58-year-old man was evaluated for ongoing leg pain, treated diabetes
insipidus and panhypopituitarism. The long bones radiographs of his legs showed
bilateral osteosclerosis of the diaphyses and metaphyses sparing the epiphyses of the
femur and tibia. A right femur bone biopsy revealed infiltration with diffuse large
foamy histiocytes, Touton-like giant cells and lymphocytic aggregates and fibrosis
diagnostic of Erdheim-Chester disease. $^{99m}$Tc-MDP-bone scan identified multiple long
bone lesions as well as T11 thoracic and L3 lumbar vertebral lesions. Unfortunately,
neither radiotherapy to his spine and knees, nor strontium-90 radionuclide nor high
dose prednisone halted the ongoing progression of his disabling pain syndrome
requiring high dose opioids. Interferon-alpha, $3\times 10^6$ units of s.c. three times per week,
later decreased to one million because of significant fatigue was very well tolerated
and allowed tapering down his opioids within three-months (Figure 2A). After 2.5 years
of interferon-$\alpha$ maintenance therapy, he is pain free, off analgesics, and the follow-up
tests show significant improvement of the bone radiographs (Figure 2B).

Patient 3:

A 53 year-old man presented with a bilateral peri-orbital congestion, erythema,
and proptosis. Exophthalmos was confirmed by Hertel exophthalmometry
measurements of 27 mm. MRI of the orbit showed bilateral intraconal masses with
increased signal on T2 weighted images.

Long bones radiographs revealed a localized area of fibrous sclerosis in the
distal left fibula. Computed tomography scans of the abdomen demonstrated
retroperitoneal fibrosis. Retro-orbital mass biopsy demonstrated Touton giant cells
with CD68-positive, S100-negative and CD1a-negative histiocytic infiltrate confirming the diagnosis of Erdheim Chester disease. The patient’s visual acuity and exophthalmos worsened despite therapy with methotrexate, cyclophosphamide, etoposide, and high-dose prednisone and vincristine.

Interferon-α was started, but the initial dose of $6 \times 10^6$ units s.c. three times per week was reduced six months later to $3 \times 10^6$ units and four months afterwards to $1 \times 10^6$ units because of fatigue. The patient tolerated low-dose interferon-α well and continued on it for an additional 16 months. Therapy was stopped as the patient’s eye exam had normalized (Figure 3). Eight months later, new skin lesions were noted and biopsy confirmed relapse. Interferon-α was recently restarted and the patient again demonstrated response.

Approval was obtained from the University of Texas M.D. Anderson Cancer Center institutional review board for these studies. Informed consent was provided according to the Declaration of Helsinki.
Results and Discussion:

Erdheim-Chester disease is a rare non-Langerhans histiocytosis of unknown etiology. The outcome of patients with Erdheim-Chester disease is worse than that for Langerhans cell histiocytosis with 59% of patients in the former group dead after a mean follow up of 32 months [2], whereas only 9% of patients with the latter disorder have succumbed after a median follow up of four years [12].

Numerous treatments have been attempted for this disease [2,6,13,14]. Corticosteroids are the traditional first-line treatment and are used to control symptoms, but generally are either ineffective or only transiently effective [2,6]. Bisphosphonates are efficient in treating osteolytic lesions in Langerhans cell histiocytosis but have only partial or temporary success in the management of bone involvement in Erdheim-Chester disease [15]. Chemotherapy can induce transient partial responses, but is often ineffective [2,16]. Cladribine has been used successfully in adult Langerhans histiocytosis, but its application in Erdheim-Chester disease is limited to two patients, one of whom responded [16,17]. Radiation, methotrexate, cyclosporine and azathioprine have not yielded sustained clinical response [3,18,19,20].

We describe the successful treatment of three patients suffering from Erdheim-Chester disease with interferon-α. The initial therapeutic dose of 3 to 6x10⁶ units s.c. three times per week, was reduced to 1x10⁶ units three times per week because of fatigue. This low dose was well tolerated and response was observed within one month with dramatic reduction in the exophthalmos and recovery of vision in two patients (case #1 and #3) whose vision was threatened by progressive disease while on high-dose chemotherapy and/or steroids. Response was also manifested by
gradual improvement in diabetes insipidus (cases #1 and #2) and in bone lesions (case #2) (Figure 2).

The mechanism(s) underlying the salutary effects of interferon-α in Erdheim-Chester are unclear but could be due to several of the diverse biological effects of this agent: maturation and activation of dendritic cells [9,10]; immune-mediated (e.g. via natural killer cells) destruction of Histiocytes; or direct antiproliferative effects [21]. There is also anecdotal evidence of clinical therapeutic benefits for interferon-alpha in other histiocytic disorders (Langerhans cell histiocytosis [22] and Rosai-Dorfaman disease [23]).

Erdheim-Chester disease is a rare and difficult-to-treat disease. All three of our patients with this disorder achieved a long-lasting response (3+, 3.5 and 4.5+ years) while receiving interferon-α. Our observations suggest that this well-tolerated treatment warrants further application and investigation in this disorder.

Acknowledgment:

There were no funding sources for this study, and the authors declare no potential conflict of interest.
References:


9. Luft T, Luetjens P, Hochrein H, Toy T, Masterman KA, Rizkalla M,
   Maliszewski C, Shortman K, Cebon J, Maraskovsky E. IFN-alpha enhances
   CD40 ligand-mediated activation of immature monocyte-derived dendritic

10. Luft T, Pang KC, Thomas E. Type I Interferons enhance the terminal

    for orbital infiltration secondary to Erdheim-Chester disease. Am J

12. Howarth DM, Gilchrist GS, Mullan BP, Wiseman GA, Edmonson JH,
    Schomberg PJ. Langerhans cell histiocytosis: diagnosis, natural history,

13. Boissel N, Wechsler B, Leblond V. Treatment of refractory Erdheim-
    Chester disease with double autologous hematopoietic stem-cell

    Erdheim-Chester disease in two patients by sequential treatment with

15. Mossetti G, Rendina D, Numis FG, Somma P, Postiglione L, Nunziata V.
    Biochemical markers of bone turnover, serum levels of interleukin-
    6/interleukin-6 soluble receptor and bisphosphonate treatment in Erdheim-

16. Myra C, Sloper L, Tighe PJ, McIntosh RS et al. Treatment of Erdheim-


Figures legends:

Figure 1:

Retro-orbital and retroperitoneal disease in patient #1.

Panel A: Before interferon-α, extensive retrobulbar soft tissue mass is seen on the T1-weighted magnetic resonance imaging before (left-side image) and after (right-side image) gadolinium injection.

Panel B: After four years of continuous interferon-α treatment, the extent of retrobulbar infiltration continues to decrease substantially.

Panel C: Clockwise from upper left, Perinephric adipose tissue reveals (upper left panel) large foamy lipid-laden histiocytes with eosinophilic cytoplasm; (upper right panel) staining positive for CD68; (lower left panel) but staining negative for CD1a; and (lower right panel) staining negative for S100 (<5% positive).

Figure 2:

Response to interferon-α in patient # 2 and 3.

Panel A: Morphine Equivalent Daily Dose (mg/day) needed to manage pain before and after interferon-α therapy. Patient required 120 mg/day of opioids before starting interferon-α. After two years, he no longer needs opioids.

Panel B: Bone radiograph of the right femur reveals mixed osteosclerotic and osteolytic lesions before treatment. Ongoing improvement is seen after two years of treatment with interferon-α.

Panel C: (Upper panel) Bilateral exophthalmos with chemosis, engorged conjunctival vessels and inferior scleral show (arrows) at presentation. Loss of eyelashes due to recent chemotherapy is noted. (Lower panel) Exophthalmos, chemosis and inferior scleral show (arrows) resolved after two years of interferon-α. Eyelashes have grown back.
Figure 2

A) Morphine Equivalent Daily Dose

B) Before interferon-α vs. After two years of interferon-α

C) Close-up images showing changes in eyes before and after interferon-α treatment.
Successful treatment of Erdheim-Chester disease, a non-Langerhans cell histiocytosis, with interferon-alpha

Fadi Braiteh, Cynthia Boxrud, Bita Esmaeli and Razelle Kurzrock